Literature DB >> 24757515

How to fight pertussis?

Nicole Guiso1.   

Abstract

Universal pertussis vaccination has successfully decreased pertussis mortality and morbidity in childhood. However, despite intensive vaccination of young children, pertussis remains a major public health problem in both developing and industrialized regions. Recent epidemics in California and Australia demonstrated that the agent of the disease is still circulating. They also revealed several aspects that must not be neglected concerning vaccine-preventable diseases. Indeed, pertussis is one of the oldest vaccine-preventable bacterial diseases, so can provide a good illustration of all of the aspects associated with the need for surveillance after the introduction of vaccination. (i) The type of vaccine: two types of pertussis vaccine, whole cell and acellular, inducing different types of immunity are now used around the world. (ii) The vaccine strategy, the vaccine coverage and the duration of vaccine immunity: pertussis epidemics provide evidence that 90% of the infants must be vaccinated, vaccination must be sufficiently early and both vaccine-induced immunity and natural infection-induced immunity to pertussis wane with time indicating that pertussis is not only a pediatric disease. (iii) The agents of the disease, Bordetella pertussis and Bordetella parapertussis: the intensive vaccination of young infants modified the herd immunity, controlled bacteria similar to the vaccine strains but not all, revealing polymorphism of the agents of the disease evidencing the importance of continuing their isolation and their surveillance as well as monitoring their antibiotic resistance. (iv) The diagnosis of the disease: the epidemics showed the importance of specific diagnostic techniques that are easy to use by medical laboratories and the availability of the reagents required. (v) Communication with the public, the health authorities and the health providers: any changes of vaccine type, vaccine strategy, characteristics of the disease, and biological diagnosis must be associated with appropriate communication with the public and training of healthcare workers. Currently, herd immunity needs to be increased by introducing vaccine boosters for adolescents and adults to protect the most vulnerable group: unvaccinated newborns.

Entities:  

Keywords:  Bordetella species; diagnosis; pertussis vaccines; surveillance

Year:  2013        PMID: 24757515      PMCID: PMC3967663          DOI: 10.1177/2051013613481348

Source DB:  PubMed          Journal:  Ther Adv Vaccines        ISSN: 2051-0136


  36 in total

Review 1.  Towards improved accuracy of Bordetella pertussis nucleic acid amplification tests.

Authors:  Michael Loeffelholz
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

2.  Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin.

Authors:  N Hegerle; A-S Paris; D Brun; G Dore; E Njamkepo; S Guillot; N Guiso
Journal:  Clin Microbiol Infect       Date:  2012-06-21       Impact factor: 8.067

3.  Pertussis vaccines: WHO position paper--recommendations.

Authors: 
Journal:  Vaccine       Date:  2010-12-01       Impact factor: 3.641

Review 4.  Duration of immunity against pertussis after natural infection or vaccination.

Authors:  Aaron M Wendelboe; Annelies Van Rie; Stefania Salmaso; Janet A Englund
Journal:  Pediatr Infect Dis J       Date:  2005-05       Impact factor: 2.129

Review 5.  Isolation, identification and characterization of Bordetella pertussis.

Authors:  N Guiso
Journal:  Dev Biol Stand       Date:  1997

6.  Pertussis cocoon strategy: would it be useful for Latin America and other developing countries?

Authors:  Rolando Ulloa-Gutierrez; Angela Gentile; Maria L Avila-Aguero
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

7.  Pertactin-negative variants of Bordetella pertussis in the United States.

Authors:  Anne Marie Queenan; Pamela K Cassiday; Alan Evangelista
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

8.  Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland.

Authors:  Alex-Mikael Barkoff; Jussi Mertsola; Sophie Guillot; Nicole Guiso; Guy Berbers; Qiushui He
Journal:  Clin Vaccine Immunol       Date:  2012-08-22

9.  Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose.

Authors:  Scott A Halperin; David Scheifele; Gaston De Serres; Francisco Noya; William Meekison; Paul Zickler; Luc Larrivée; Joanne M Langley; Shelly A McNeil; Simon Dobson; Emilia Jordanov; Manoj Thakur; Michael D Decker; David R Johnson
Journal:  Vaccine       Date:  2011-11-21       Impact factor: 3.641

10.  Clinical definitions of pertussis: Summary of a Global Pertussis Initiative roundtable meeting, February 2011.

Authors:  James D Cherry; Tina Tan; Carl-Heinz Wirsing von König; Kevin D Forsyth; Usa Thisyakorn; David Greenberg; David Johnson; Colin Marchant; Stanley Plotkin
Journal:  Clin Infect Dis       Date:  2012-03-19       Impact factor: 9.079

View more
  4 in total

Review 1.  The role of Toll-like receptor 4 polymorphisms in vaccine immune response.

Authors:  P Pellegrino; F S Falvella; S Cheli; C Perrotta; E Clementi; S Radice
Journal:  Pharmacogenomics J       Date:  2015-03-31       Impact factor: 3.550

Review 2.  Pertussis.

Authors:  Giovanni Gabutti; Chiara Azzari; Paolo Bonanni; Rosa Prato; Alberto E Tozzi; Alessandro Zanetti; Gianvincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

3.  Bordetella pertussis: an underreported pathogen in pediatric respiratory infections, a prospective cohort study.

Authors:  Gertrude van den Brink; Jérôme O Wishaupt; Jacob C Douma; Nico G Hartwig; Florens G A Versteegh
Journal:  BMC Infect Dis       Date:  2014-09-30       Impact factor: 3.090

4.  Study on Toxicity Reduction and Potency Induction in Whole-cell Pertussis Vaccine by Developing a New Optimal Inactivation Condition Processed on Bordetella pertussis.

Authors:  Naser Mohammadpour Dounighi; Mehdi Razzaghi-Abyane; Mojtaba Nofeli; Hossein Zolfagharian; Fereshteh Shahcheraghi
Journal:  Jundishapur J Microbiol       Date:  2016-07-09       Impact factor: 0.747

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.